SI1082302T1 - A vla-4 inhibitor: omepupa-v - Google Patents
A vla-4 inhibitor: omepupa-vInfo
- Publication number
- SI1082302T1 SI1082302T1 SI9930526T SI9930526T SI1082302T1 SI 1082302 T1 SI1082302 T1 SI 1082302T1 SI 9930526 T SI9930526 T SI 9930526T SI 9930526 T SI9930526 T SI 9930526T SI 1082302 T1 SI1082302 T1 SI 1082302T1
- Authority
- SI
- Slovenia
- Prior art keywords
- omepupa
- inhibitor
- vla
- cell
- methylphenylamino
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000021164 cell adhesion Effects 0.000 abstract 2
- -1 2-methylphenylamino Chemical group 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 229940000635 beta-alanine Drugs 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8706498P | 1998-05-28 | 1998-05-28 | |
| EP99926019A EP1082302B1 (en) | 1998-05-28 | 1999-05-28 | A vla-4 inhibitor: omepupa-v |
| PCT/US1999/011924 WO1999061421A1 (en) | 1998-05-28 | 1999-05-28 | A NOVEL VLA-4 INHIBITOR: oMePUPA-V |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1082302T1 true SI1082302T1 (en) | 2004-06-30 |
Family
ID=22202907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9930526T SI1082302T1 (en) | 1998-05-28 | 1999-05-28 | A vla-4 inhibitor: omepupa-v |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6495525B1 (cs) |
| EP (1) | EP1082302B1 (cs) |
| JP (1) | JP2002516309A (cs) |
| KR (1) | KR100636713B1 (cs) |
| CN (1) | CN1148350C (cs) |
| AT (1) | ATE256659T1 (cs) |
| AU (1) | AU764108B2 (cs) |
| BG (1) | BG65021B1 (cs) |
| CA (1) | CA2333656C (cs) |
| CZ (1) | CZ298413B6 (cs) |
| DE (1) | DE69913687T2 (cs) |
| DK (1) | DK1082302T3 (cs) |
| EA (1) | EA002988B1 (cs) |
| EE (1) | EE04639B1 (cs) |
| ES (1) | ES2211096T3 (cs) |
| HU (1) | HUP0102255A3 (cs) |
| IL (1) | IL139967A (cs) |
| IS (1) | IS5737A (cs) |
| MX (1) | MXPA00011774A (cs) |
| NO (1) | NO317990B1 (cs) |
| NZ (1) | NZ509199A (cs) |
| PL (1) | PL198189B1 (cs) |
| PT (1) | PT1082302E (cs) |
| SI (1) | SI1082302T1 (cs) |
| SK (1) | SK285280B6 (cs) |
| TR (1) | TR200100190T2 (cs) |
| UA (1) | UA65623C2 (cs) |
| WO (1) | WO1999061421A1 (cs) |
| YU (1) | YU75500A (cs) |
| ZA (1) | ZA200007300B (cs) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| EP1034164B1 (en) * | 1997-11-24 | 2004-05-19 | Merck & Co., Inc. | Substituted beta-alanine derivatives as cell adhesion inhibitors |
| AU757873B2 (en) | 1998-09-14 | 2003-03-06 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| US7618630B2 (en) | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| US6525069B1 (en) * | 1998-12-18 | 2003-02-25 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| RS50470B (sr) | 1999-08-13 | 2010-03-02 | Biogen Idec Ma Inc. | Inhibitori ćelijske adhezije |
| EA004673B1 (ru) | 1999-12-28 | 2004-06-24 | Пфайзер Продактс Инк. | Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний |
| TWI312779B (cs) | 2000-12-28 | 2009-08-01 | Daiichi Seiyaku Co | |
| CA2528586A1 (en) | 2003-07-24 | 2005-02-03 | Daiichi Pharmaceutical Co., Ltd. | Cyclohexanecarboxylic acid compound |
| US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
| US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
| GT200500321A (es) * | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
| US7685367B2 (en) * | 2006-03-08 | 2010-03-23 | Microsoft Corporation | Multi-cache cooperation for response output caching |
| WO2008017025A2 (en) * | 2006-08-02 | 2008-02-07 | Genzyme Corporation | Combination therapy |
| US20100150915A1 (en) | 2007-02-20 | 2010-06-17 | Stewart Edward J | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
| JP5639039B2 (ja) | 2008-04-11 | 2014-12-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| SI3202789T1 (sl) | 2010-04-16 | 2020-11-30 | Biogen Ma Inc. | Protitelesa anti-vla 4 |
| US20150202287A1 (en) | 2012-08-30 | 2015-07-23 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| JP7457661B2 (ja) | 2018-06-04 | 2024-03-28 | バイオジェン・エムエイ・インコーポレイテッド | 低減したエフェクター機能を有する抗ｖｌａ－４抗体 |
| WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
| PE20211866A1 (es) | 2018-10-30 | 2021-09-21 | Gilead Sciences Inc | Derivados de quinolina como inhibidores de la integrina alfa4beta7 |
| US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| EP3873900B1 (en) | 2018-10-30 | 2025-01-08 | Gilead Sciences, Inc. | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| KR20220047323A (ko) | 2019-08-14 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1149971B (it) | 1979-06-11 | 1986-12-10 | Syntex Inc | Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante |
| US4725583A (en) | 1985-01-23 | 1988-02-16 | Abbott Laboratories | Functionalized peptidylaminoalcohols |
| US4826815A (en) | 1985-05-17 | 1989-05-02 | Abbott Laboratories | Renin inhibiting compounds |
| DK163689A (da) | 1988-04-08 | 1989-10-30 | Sandoz Ag | Peptidderivater |
| EP0506748B1 (en) | 1989-12-22 | 1995-12-13 | Commonwealth Scientific And Industrial Research Organisation | Amino acids, peptides or derivatives thereof coupled to fats |
| CA2043741C (en) | 1990-06-07 | 2003-04-01 | Kiyofumi Ishikawa | Endothelin antagonistic peptide derivatives |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US5260277A (en) * | 1990-09-10 | 1993-11-09 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
| WO1992008464A1 (en) | 1990-11-15 | 1992-05-29 | Tanabe Seiyaku Co. Ltd. | Substituted urea and related cell adhesion modulation compounds |
| EP0519748B1 (en) | 1991-06-21 | 1998-09-02 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
| WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
| US5352667A (en) | 1991-11-22 | 1994-10-04 | Ofer Lider | Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them |
| WO1993012809A1 (en) | 1991-12-24 | 1993-07-08 | Fred Hutchinson Cancer Research Center | Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv |
| DE4212304A1 (de) | 1992-04-13 | 1993-10-14 | Cassella Ag | Asparaginsäurederivate, ihre Herstellung und Verwendung |
| IL102646A (en) | 1992-07-26 | 1996-05-14 | Yeda Res & Dev | Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them |
| SG52262A1 (en) | 1993-01-08 | 1998-09-28 | Tanabe Seiyaku Co | Peptide inhibitors of cell adhesion |
| US5314902A (en) | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
| DE4309867A1 (de) | 1993-03-26 | 1994-09-29 | Cassella Ag | Neue Harnstoffderivate, ihre Herstellung und Verwendung |
| DK0695547T3 (da) | 1993-04-09 | 2001-10-08 | Toyama Chemical Co Ltd | Immunmodulator, celleadhæsionsinhibitor og middel til behandling og forebyggelse af autoimmunsygdomme |
| AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5770573A (en) | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5434188A (en) | 1994-03-07 | 1995-07-18 | Warner-Lambert Company | 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| SG158733A1 (en) * | 1996-07-25 | 2010-02-26 | Biogen Idec Inc | Cell adhesion inhibitors |
-
1999
- 1999-05-28 MX MXPA00011774A patent/MXPA00011774A/es not_active IP Right Cessation
- 1999-05-28 PT PT99926019T patent/PT1082302E/pt unknown
- 1999-05-28 EE EEP200000698A patent/EE04639B1/xx not_active IP Right Cessation
- 1999-05-28 EA EA200001236A patent/EA002988B1/ru not_active IP Right Cessation
- 1999-05-28 AT AT99926019T patent/ATE256659T1/de not_active IP Right Cessation
- 1999-05-28 DK DK99926019T patent/DK1082302T3/da active
- 1999-05-28 TR TR2001/00190T patent/TR200100190T2/xx unknown
- 1999-05-28 EP EP99926019A patent/EP1082302B1/en not_active Expired - Lifetime
- 1999-05-28 CN CNB998080020A patent/CN1148350C/zh not_active Expired - Fee Related
- 1999-05-28 WO PCT/US1999/011924 patent/WO1999061421A1/en not_active Ceased
- 1999-05-28 HU HU0102255A patent/HUP0102255A3/hu unknown
- 1999-05-28 KR KR1020007013421A patent/KR100636713B1/ko not_active Expired - Fee Related
- 1999-05-28 PL PL344440A patent/PL198189B1/pl not_active IP Right Cessation
- 1999-05-28 UA UA2000127603A patent/UA65623C2/uk unknown
- 1999-05-28 DE DE69913687T patent/DE69913687T2/de not_active Expired - Fee Related
- 1999-05-28 AU AU42192/99A patent/AU764108B2/en not_active Ceased
- 1999-05-28 YU YU75500A patent/YU75500A/sh unknown
- 1999-05-28 CA CA002333656A patent/CA2333656C/en not_active Expired - Fee Related
- 1999-05-28 ES ES99926019T patent/ES2211096T3/es not_active Expired - Lifetime
- 1999-05-28 SK SK1810-2000A patent/SK285280B6/sk not_active IP Right Cessation
- 1999-05-28 JP JP2000550827A patent/JP2002516309A/ja active Pending
- 1999-05-28 NZ NZ509199A patent/NZ509199A/en unknown
- 1999-05-28 SI SI9930526T patent/SI1082302T1/xx unknown
- 1999-05-28 CZ CZ20004425A patent/CZ298413B6/cs not_active IP Right Cessation
- 1999-05-28 IL IL13996799A patent/IL139967A/xx not_active IP Right Cessation
-
2000
- 2000-11-28 US US09/724,107 patent/US6495525B1/en not_active Expired - Fee Related
- 2000-11-28 IS IS5737A patent/IS5737A/is unknown
- 2000-11-28 NO NO20006023A patent/NO317990B1/no unknown
- 2000-12-08 ZA ZA200007300A patent/ZA200007300B/en unknown
- 2000-12-18 BG BG105060A patent/BG65021B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1082302T1 (en) | A vla-4 inhibitor: omepupa-v | |
| HUP0201214A3 (en) | Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use | |
| HUP9802315A3 (en) | Thrombin inhibitors, process for producing them and use of them for producing pharmaceutical compositions | |
| ZA200108082B (en) | Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth. | |
| HUP0001285A3 (en) | Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them | |
| HUP0105144A3 (en) | Hepatitis c inhibitor tri-peptides, process for production thereof, pharmaceutical compositions copmprising thereof, intermediates and their use | |
| HUP9900728A3 (en) | Peptide derivatives as thrombin inhibitors, process for producing them and pharmaceutical compositions containing them | |
| AP1787A (en) | Novel perindopril salt and pharmaceutical compositions containing same. | |
| GR3036305T3 (en) | Chiral methyl phenyl oxazolidinones | |
| MY125428A (en) | ?-carboline drug products | |
| HUP9801227A3 (en) | Pharmaceutical compositions comprising monoamine oxidase b inhibitors and their use | |
| IL124883A0 (en) | Amidino protease inhibitors and pharmaceutical compositions containing the same | |
| ATE239709T1 (de) | Racemisches huperzin a | |
| BR9912010A (pt) | Polimorfo de um produto farmacêutico | |
| AU1031697A (en) | Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions | |
| HUP0101899A3 (en) | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes, pharmaceutical compositions comprising thereof and their use | |
| AU2003271811A1 (en) | Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same | |
| AU6633596A (en) | Improved therapeutic agents | |
| MX9708394A (es) | Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion. | |
| AU2002341555A1 (en) | Levothyroxine pharmaceutical compositions, methods of making and methods of administration | |
| AU8847098A (en) | Pharmaceutical compositions comprising cefuroxime axetil | |
| AU2001261519A1 (en) | Methods of affecting laminin 5 processing | |
| AU3183801A (en) | Product comprising a heterotrimeric G protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension | |
| ZA200104508B (en) | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors. | |
| WO2000063350A3 (en) | Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis |